DE LAURENTIIS, MICHELINO
 Distribuzione geografica
Continente #
NA - Nord America 2.576
EU - Europa 1.611
AS - Asia 534
AF - Africa 43
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.770
Nazione #
US - Stati Uniti d'America 2.507
IT - Italia 599
CN - Cina 391
NL - Olanda 251
IE - Irlanda 182
UA - Ucraina 154
FI - Finlandia 138
DE - Germania 134
VN - Vietnam 99
CA - Canada 66
GB - Regno Unito 48
SE - Svezia 48
CI - Costa d'Avorio 36
IN - India 26
FR - Francia 25
RU - Federazione Russa 7
SG - Singapore 7
TW - Taiwan 5
BE - Belgio 4
BG - Bulgaria 4
BZ - Belize 3
EG - Egitto 3
HK - Hong Kong 3
IR - Iran 3
ZA - Sudafrica 3
BR - Brasile 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
ES - Italia 2
EU - Europa 2
LI - Liechtenstein 2
MD - Moldavia 2
SI - Slovenia 2
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
LU - Lussemburgo 1
NO - Norvegia 1
PL - Polonia 1
RS - Serbia 1
TN - Tunisia 1
Totale 4.770
Città #
Chandler 466
Millbury 270
Amsterdam 240
Jacksonville 160
Princeton 157
Ashburn 118
Nanjing 115
Naples 105
Beijing 98
Dong Ket 98
Napoli 92
Wilmington 88
Des Moines 78
Boston 64
Ottawa 62
Lawrence 49
Nanchang 41
Dublin 30
Hebei 26
Tianjin 23
Norwalk 21
Shenyang 21
Jiaxing 20
Rome 17
Pune 16
Falls Church 15
Houston 14
Milan 14
Boardman 13
Kunming 11
Seattle 11
Kronberg 9
Salerno 9
Changsha 8
Fairfield 8
Giugliano In Campania 8
Woodbridge 8
New York 7
Washington 7
Casoria 6
Indiana 6
Pomigliano d'Arco 6
Redwood City 6
Bologna 5
Dearborn 5
Formia 5
Lanzhou 5
Sant'Agnello 5
Santa Clara 5
Catanzaro 4
Changchun 4
Kortrijk 4
Leawood 4
Samara 4
Sofia 4
Wuhan 4
Angri 3
Battipaglia 3
Belize City 3
Edinburgh 3
Frankfurt am Main 3
Johannesburg 3
Montauro 3
Nuremberg 3
Pellezzano 3
Perugia 3
Porto 3
San Mateo 3
Sunnyvale 3
Ann Arbor 2
Augusta 2
Bernalda 2
Boydton 2
Brno 2
Cairo 2
Caivano 2
Cambridge 2
Caserta 2
Catania 2
Cernusco sul Naviglio 2
Chicago 2
Chisinau 2
Duncan 2
Düsseldorf 2
Ercolano 2
Florence 2
Fort Worth 2
Glendale 2
Jinan 2
L’Aquila 2
Magenta 2
Modena 2
Mugnano di Napoli 2
Palermo 2
Rapolla 2
Ravenna 2
Redmond 2
Richmond 2
San Jose 2
Scilla 2
Totale 2.800
Nome #
Manuale di Oncologia Clinica 95
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 82
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 76
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 70
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 59
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 59
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 56
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 53
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 52
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. 51
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 50
Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5 50
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 50
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 47
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 43
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 43
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 43
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 42
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 41
An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer 39
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 39
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 38
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 38
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 38
Amyloid in bone marrow smears of patients affected by multiple myeloma. 36
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 36
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 36
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 36
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 36
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 36
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 35
A predictive index of axillary nodal involvement in operable breast cancer. 35
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 35
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”, 34
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 34
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. 33
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 33
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial 33
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 32
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 32
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial 32
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer 32
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 32
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 31
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 31
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 31
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 31
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer 31
Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells 31
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 31
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 30
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 30
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 30
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab 30
Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy 30
Triple-Negative Breast Cancer comparison with Canine Mammary Tumors from light microscopy to molecular pathology 30
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 29
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 29
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial 29
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients 29
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients 29
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 29
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 28
Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo 28
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 27
null 27
A technique for using neural network analysis to perform survival analysis of censored data. 27
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 27
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 27
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. 27
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA 26
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. 26
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 26
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 26
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. 26
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series 26
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study 26
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 25
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. 25
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 25
Treatment of triple negative brest cancer (TNBC): current options and future perspectives. 25
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 25
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancer 25
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype 25
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial 25
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. 24
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 24
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 24
Survival Analysis by means of a novel Neural Network Model 23
Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 23
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 23
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. 22
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. 22
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. 22
Survival, quality of life and breast cancer. 22
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 22
Prognostic significance of multifocality in primary breast cancer. 22
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 22
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. 21
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. 21
Totale 3.410
Categoria #
all - tutte 22.167
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.167


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 2 12 1 10
2019/2020597 208 4 34 7 40 15 9 16 13 81 79 91
2020/2021626 20 27 72 46 45 78 49 11 103 17 50 108
2021/20221.114 9 4 10 4 21 50 15 45 175 90 202 489
2022/20231.370 227 96 39 79 133 129 12 82 198 250 103 22
2023/2024702 44 170 163 81 59 80 13 82 10 0 0 0
Totale 5.114